These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29747600)

  • 1. VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
    Martini M; de Pascalis I; D'Alessandris QG; Fiorentino V; Pierconti F; Marei HE; Ricci-Vitiani L; Pallini R; Larocca LM
    BMC Cancer; 2018 May; 18(1):553. PubMed ID: 29747600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
    Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma.
    Labussière M; Cheneau C; Prahst C; Gállego Pérez-Larraya J; Farina P; Lombardi G; Mokhtari K; Rahimian A; Delattre JY; Eichmann A; Sanson M
    Cancer Invest; 2016; 34(1):39-44. PubMed ID: 26735326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.
    Tabouret E; Boudouresque F; Barrie M; Matta M; Boucard C; Loundou A; Carpentier A; Sanson M; Metellus P; Figarella-Branger D; Ouafik L; Chinot O
    Neuro Oncol; 2014 Mar; 16(3):392-9. PubMed ID: 24327581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
    Nayak L; Molinaro AM; Peters K; Clarke JL; Jordan JT; de Groot J; Nghiemphu L; Kaley T; Colman H; McCluskey C; Gaffey S; Smith TR; Cote DJ; Severgnini M; Yearley JH; Zhao Q; Blumenschein WM; Duda DG; Muzikansky A; Jain RK; Wen PY; Reardon DA
    Clin Cancer Res; 2021 Feb; 27(4):1048-1057. PubMed ID: 33199490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
    Lee EQ; Muzikansky A; Duda DG; Gaffey S; Dietrich J; Nayak L; Chukwueke UN; Beroukhim R; Doherty L; Laub CK; LaFrankie D; Fontana B; Stefanik J; Ruland S; Caruso V; Bruno J; Ligon K; Reardon DA; Wen PY
    Cancer Med; 2019 Oct; 8(13):5988-5994. PubMed ID: 31444999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
    Kickingereder P; Götz M; Muschelli J; Wick A; Neuberger U; Shinohara RT; Sill M; Nowosielski M; Schlemmer HP; Radbruch A; Wick W; Bendszus M; Maier-Hein KH; Bonekamp D
    Clin Cancer Res; 2016 Dec; 22(23):5765-5771. PubMed ID: 27803067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.
    Morisse MC; Etienne-Selloum N; Bello-Roufai D; Blonski M; Taillandier L; Lorgis V; Noël G; Ahle G; Durán-Peña A; Boone M; Chauffert B
    J Neurooncol; 2019 Sep; 144(2):419-426. PubMed ID: 31325146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.
    Bertaut A; Truntzer C; Madkouri R; Kaderbhai CG; Derangère V; Vincent J; Chauffert B; Aubriot-Lorton MH; Farah W; Mourier KL; Boidot R; Ghiringhelli F
    Oncotarget; 2016 Oct; 7(43):70948-70958. PubMed ID: 27487142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1.
    Falchetti ML; D'Alessandris QG; Pacioni S; Buccarelli M; Morgante L; Giannetti S; Lulli V; Martini M; Larocca LM; Vakana E; Stancato L; Ricci-Vitiani L; Pallini R
    Int J Cancer; 2019 Mar; 144(6):1331-1344. PubMed ID: 30414187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
    Steidl E; Pilatus U; Hattingen E; Steinbach JP; Zanella F; Ronellenfitsch MW; Bähr O
    PLoS One; 2016; 11(12):e0168113. PubMed ID: 28033329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab.
    Di Stefano AL; Labussiere M; Lombardi G; Eoli M; Bianchessi D; Pasqualetti F; Farina P; Cuzzubbo S; Gallego-Perez-Larraya J; Boisselier B; Ducray F; Cheneau C; Moglia A; Finocchiaro G; Marie Y; Rahimian A; Hoang-Xuan K; Delattre JY; Mokhtari K; Sanson M
    J Neurooncol; 2015 Feb; 121(3):499-504. PubMed ID: 25488073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
    Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
    Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
    Toh CH; Liau CT; Wei KC; Castillo M
    J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
    Winkler F; Osswald M; Wick W
    Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
    Sinkó D; Nemeskéri C
    Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
    Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
    Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.